Drug Landscape ›
Simvastatin 20mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 122
Most-reported reactions
Myalgia — 29 reports (23.77%) Fatigue — 14 reports (11.48%) Pain In Extremity — 14 reports (11.48%) Drug Interaction — 11 reports (9.02%) Muscle Spasms — 11 reports (9.02%) Abdominal Discomfort — 9 reports (7.38%) Arthralgia — 9 reports (7.38%) Asthenia — 9 reports (7.38%) Blood Creatine Phosphokinase Increased — 8 reports (6.56%) Dizziness — 8 reports (6.56%)
Source database →
Simvastatin 20mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Simvastatin 20mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Simvastatin 20mg in United States?
University of Oxford is the originator. The local marketing authorisation holder may differ — check the official source linked above.